Abstract
Abnormalities of striatal function have been implicated in several major neurological and psychiatric disorders, including Parkinson's disease, schizophrenia and depression. Adenosine, via activation of A2A receptors, antagonizes dopamine signaling at D2 receptors and A2A receptor antagonists have been tested as therapeutic agents for Parkinson's disease. We found a direct physical interaction between the G protein–coupled A2A receptor (A2AR) and the receptor tyrosine kinase fibroblast growth factor receptor (FGFR). Concomitant activation of these two classes of receptors, but not individual activation of either one alone, caused a robust activation of the MAPK/ERK pathway, differentiation and neurite extension of PC12 cells, spine morphogenesis in primary neuronal cultures, and cortico-striatal plasticity that was induced by a previously unknown A2AR/FGFR-dependent mechanism. The discovery of a direct physical interaction between the A2A and FGF receptors and the robust physiological consequences of this association shed light on the mechanism underlying FGF functions as a co-transmitter and open new avenues for therapeutic interventions.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Fredholm, B.B. Purinoceptors in the nervous system. Pharmacol. Toxicol. 76, 228–239 (1995).
Zimmermann, H. Biochemistry, localization and functional roles of ecto-nucleotidases in the nervous system. Prog. Neurobiol. 49, 589–618 (1996).
Lindskog, M. et al. Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine. Nature 418, 774–778 (2002).
Durcan, M.J. & Morgan, P.F. Evidence for adenosine A2 receptor involvement in the hypomobility effects of adenosine analogues in mice. Eur. J. Pharmacol. 168, 285–290 (1989).
Fuxe, K. et al. Intramembrane receptor-receptor interactions: a novel principle in molecular medicine. J. Neural Transm. 114, 49–75 (2007).
Ornitz, D.M. & Itoh, N. Fibroblast growth factors. Genome Biol. 2, 3005.1–3005.12 (2001).
Dono, R. Fibroblast growth factors as regulators of central nervous system development and function. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284, R867–R881 (2003).
Reuss, B. von Bohlen und Halbach, O. Fibroblast growth factors and their receptors in the central nervous system. Cell Tissue Res. 313, 139–157 (2003).
Umemori, H., Linhoff, M.W., Ornitz, D.M. & Sanes, J.R. FGF22 and its close relatives are presynaptic organizing molecules in the mammalian brain. Cell 118, 257–270 (2004).
Forget, C., Stewart, J. & Trudeau, L.E. Impact of basic FGF expression in astrocytes on dopamine neuron synaptic function and development. Eur. J. Neurosci. 23, 608–616 (2006).
Fumagalli, F., Di Pasquale, L., Caffino, L., Racagni, G. & Riva, M.A. Stress and cocaine interact to modulate basic fibroblast growth factor (FGF-2) expression in rat brain. Psychopharmacology (Berl). 196, 357–364 (2007).
Grothe, C. & Timmer, M. The physiological and pharmacological role of basic fibroblast growth factor in the dopaminergic nigrostriatal system. Brain Res. Rev. 54, 80–91 (2007).
Claus, P., Werner, S., Timmer, M. & Grothe, C. Expression of the fibroblast growth factor-2 isoforms and the FGF receptor 1–4 transcripts in the rat model system of Parkinson's disease. Neurosci. Lett. 360, 117–120 (2004).
Mohammadi, M. et al. A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2 domain of phospholipase C-gamma 1. Mol. Cell. Biol. 11, 5068–5078 (1991).
Sorokin, A., Mohammadi, M., Huang, J. & Schlessinger, J. Internalization of fibroblast growth factor receptor is inhibited by a point mutation at tyrosine 766. J. Biol. Chem. 269, 17056–17061 (1994).
Hayashi, H., Ishisaki, A., Suzuki, M. & Imamura, T. BMP-2 augments FGF-induced differentiation of PC12 cells through upregulation of FGF receptor 1 expression. J. Cell Sci. 114, 1387–1395 (2001).
Kobayashi, S. & Millhorn, D.E. Stimulation of expression for the adenosine A2A receptor gene by hypoxia in PC12 cells. A potential role in cell protection. J. Biol. Chem. 274, 20358–20365 (1999).
Vaudry, D., Stork, P.J., Lazarovici, P. & Eiden, L.E. Signaling pathways for PC12 cell differentiation: making the right connections. Science 296, 1648–1649 (2002).
Wu, G.Y., Deisseroth, K. & Tsien, R.W. Spaced stimuli stabilize MAPK pathway activation and its effects on dendritic morphology. Nat. Neurosci. 4, 151–158 (2001).
Goldin, M. & Segal, M. Protein kinase C and ERK involvement in dendritic spine plasticity in cultured rodent hippocampal neurons. Eur. J. Neurosci. 17, 2529–2539 (2003).
Alonso, M., Medina, J.H. & Pozzo-Miller, L. ERK1/2 activation is necessary for BDNF to increase dendritic spine density in hippocampal CA1 pyramidal neurons. Learn. Mem. 11, 172–178 (2004).
d'Alcantara, P., Ledent, C., Swillens, S. & Schiffmann, S.N. Inactivation of adenosine A2A receptor impairs long term potentiation in the accumbens nucleus without altering basal synaptic transmission. Neuroscience 107, 455–464 (2001).
Thomas, G.M. & Huganir, R.L. MAPK cascade signaling and synaptic plasticity. Nat. Rev. Neurosci. 5, 173–183 (2004).
Surmeier, D.J., Ding, J., Day, M., Wang, Z. & Shen, W. D1 and D2 dopamine- receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci. 30, 228–235 (2007).
Calabresi, P., Picconi, B., Tozzi, A. & Di Filippo, M. Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci. 30, 211–219 (2007).
Lee, S.P., O'Dowd, B.F. & George, S.R. Homo- and hetero-oligomerization of G protein–coupled receptors. Life Sci. 74, 173–180 (2003).
Schlessinger, J. Signal transduction by allosteric receptor oligomerization. Trends Biochem. Sci. 13, 443–447 (1988).
Jahangeer, S. & Rodbell, M. The disaggregation theory of signal transduction revisited: further evidence that G proteins are multimeric and disaggregate to monomers when activated. Proc. Natl. Acad. Sci. USA 90, 8782–8786 (1993).
Thomason, P.A., Wolanin, P.M. & Stock, J.B. Signal transduction: receptor clusters as information processing arrays. Curr. Biol. 12, R399–R401 (2002).
Ferguson, S.S. Receptor tyrosine kinase transactivation: fine-tuning synaptic transmission. Trends Neurosci. 26, 119–122 (2003).
Shah, B.H. & Catt, K.J. GPCR-mediated transactivation of RTKs in the CNS: mechanisms and consequences. Trends Neurosci. 27, 48–53 (2004).
Claus, P., Werner, S., Timmer, M. & Grothe, C. Expression of the fibroblast growth factor-2 isoforms and the FGF receptor 1–4 transcripts in the rat model system of Parkinson's disease. Neurosci. Lett. 360, 117–120 (2004).
Valjent, E. et al. Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc. Natl. Acad. Sci. USA 102, 491–496 (2005).
Ding, J., Peterson, J.D. & Surmeier, D.J. Corticostriatal and thalamostriatal synapses have distinctive properties. J. Neurosci. 28, 6483–5492 (2008).
Tepper, J.M., Wilson, C.J. & Koos, T. Feedforward and feedback inhibition in neostriatal GABAergic spiny neurons. Brain Res. Rev. 58, 272–281 (2007).
Calabresi, P., Picconi, B., Tozzi, A. & Di Filippo, M. Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci. 30, 211–219 (2007).
Song, W.J., Tkatch, T. & Surmeier, D.J. Adenosine receptor expression and modulation of Ca2+ channels in rat striatal cholinergic interneurons. J. Neurophysiol. 83, 322–332 (2000).
Ferre, S., Fredholm, B.B., Morelli, M., Popoli, P. & Fuxe, K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci. 20, 482–487 (1997).
Ferre, S. Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia. Psychopharmacology (Berl.) 133, 107–120 (1997).
Centonze, D., Picconi, B., Gubellini, P., Bernardi, G. & Calabresi, P. Dopaminergic control of synaptic plasticity in the dorsal striatum. Eur. J. Neurosci. 13, 1071–1077 (2001).
Kerr, J.N. & Wickens, J.R. Dopamine D-1/D-5 receptor activation is required for long-term potentiation in the rat neostriatum in vitro. J. Neurophysiol. 85, 117–124 (2001).
Surmeier, D.J., Song, W.J. & Yan, Z. Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J. Neurosci. 16, 6579–6591 (1996).
Gerfen, C.R. et al. D1 and D2 dopamine receptor–regulated gene expression of striatonigral and striatopallidal neurons. Science 250, 1429–1432 (1990).
Kreitzer, A.C. & Malenka, R.C. Dopamine modulation of state-dependent endocannabinoid release and long-term depression in the striatum. J. Neurosci. 25, 10537–10545 (2005).
Song, B.W., Vinters, H.V., Wu, D. & Pardridge, W.M. Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector. J. Pharmacol. Exp. Ther. 301, 605–610 (2002).
Flajolet, M. et al. A genomic approach of the hepatitis C virus generates a protein interaction map. Gene 242, 369–379 (2000).
Flajolet, M. et al. Protein phosphatase 2C binds selectively to and dephosphorylates metabotropic glutamate receptor 3. Proc. Natl. Acad. Sci. USA 100, 16006–16011 (2003).
Futter, M. et al. Phosphorylation of spinophilin by ERK and cyclin-dependent PK 5 (Cdk5). Proc. Natl. Acad. Sci. USA 102, 3489–3494 (2005).
Acknowledgements
We are grateful to J. Rogers and H. Rebholz for critical reading of the manuscript, and to A. Nishi and G. Fisone for helpful discussions. This work was supported in part by grants from the US National Institutes of Health (MH074866 to P.G., A.C.N. and D.J.S., and NS34696 to D.J.S), the Simons Foundation, the Picower Foundation, and by award W81XWH-04-2-0009 from the US Medical Research and Materiel Command Neurotoxin Exposure Treatment Program to Intra-Cellular Therapies. M.F. was supported in part by a 2006 National Alliance for Research on Schizophrenia And Depression Young Investigator Award.
Author information
Authors and Affiliations
Corresponding author
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–4 (PDF 100 kb)
Rights and permissions
About this article
Cite this article
Flajolet, M., Wang, Z., Futter, M. et al. FGF acts as a co-transmitter through adenosine A2A receptor to regulate synaptic plasticity. Nat Neurosci 11, 1402–1409 (2008). https://doi.org/10.1038/nn.2216
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nn.2216
This article is cited by
-
The impact of purine nucleosides on neuroplasticity in the adult brain
Purinergic Signalling (2024)
-
Purinergic signaling: a potential therapeutic target for depression and chronic pain
Purinergic Signalling (2023)
-
Fibroblast Growth Factor Signalling in the Diseased Nervous System
Molecular Neurobiology (2021)
-
The coming together of allosteric and phosphorylation mechanisms in the molecular integration of A2A heteroreceptor complexes in the dorsal and ventral striatal-pallidal GABA neurons
Pharmacological Reports (2021)
-
The belated US FDA approval of the adenosine A2A receptor antagonist istradefylline for treatment of Parkinson’s disease
Purinergic Signalling (2020)